Corcept Therapeutics Incorporated (0I3Q.L) LSE

Currency In USD

AD

Valuation

Market Cap3.53B
Enterprise Value3.42B
P/E Ratio204.18
PEG Ratio-3.16
Price/Sales Ratio12.82
Price/Book Ratio15.04
Enterprise/Revenue12.7
Enterprise/EBITDA689.77

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterMarch 31, 2026

Profitability

Profit Margin0.06
Operating Margin-0.01
AD

Management Effectiveness

Return On Assets0.06
Return On Equity0.08

Income Statement

Revenue761.41M
Revenue/Share7.36
Gross Profit748.43M
EBITDA46.69M
Net Income99.65M
Diluted EPS0.82

Balance Sheet

Total Cash338.18M
Total Cash/Share3.24
Total Debt9.64M
Total Debt/Equity0.02
Current Ratio2.86
Book Value Per Share6.11

Price History

52-Week Change26.41
52-Week High96.64
52-Week Low20.76
Moving Average 50 Days23.44
Moving Average 200 Days26

Statistics

Average Volume2,318
Shares Outstanding103.95M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A
AD